YOLFTbeta
Cengild Medical Berhad

Cengild Medical Berhad

0243 · KLSE · Healthcare / Medical Care Facilities

0.155MYR+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close0.155
Open0.155
Day Range0.15 – 0.155
52-Week Range0.1847 – 0.2497
Volume149.90K
Market Cap162.42M
P/E (TTM)19.50
Forward P/E0.00
EPS0.01
Dividend Yield0.32%
Beta0.08
50-Day Avg0.1956
200-Day Avg0.2102

About

Cengild Medical Berhad, an investment holding company, operates a medical center in Malaysia. The company offers various care and treatment consultant services for gastrointestinal and liver diseases, morbid obesity, and oncology and urological conditions; general cardiology and gynecology assessment; gastroenterology and hepatology; anesthesiology, general surgery, internal medicine, and radiology; ear, nose and throat; gastrointestinal surgeries, including upper gastrointestinal, hepatobiliary, pancreatic, colorectal surgery, and bariatric surgery; and chemotherapy. It also provides medical management services; nursing services and clinical support services; clinical laboratory and pharmacy; operating theatre, endoscopy, radiology and imaging services; accident and emergency care, and health screenings; and consultant services. Cengild Medical Berhad was founded in 2017 and is based in Kuala Lumpur, Malaysia.

Company Details

  • SectorHealthcare
  • IndustryMedical Care Facilities
  • CEOMs. Wai Fern Lee
  • Employees151
  • HeadquartersNexus @ Bangsar South, Kuala Lumpur, Malaysia, 59200, Malaysia
  • Websitehttps://cengild.com

Leadership

  • Dr. Huck Joo TanExecutive Chairman & Medical Director · b. 1968
  • Dr. Mohamed Akhtar Bin Mohamed Ditali QureshiHead of Medical Adv. Board and Operating Theatre & Central Sterile Supply Dept. and Exec. Director · b. 1961
  • Ms. Wai Fern LeeGroup Chief Executive Officer · b. 1975
  • Ms. Suik Hae WongChief Financial Officer · b. 1982
  • Dr. Siew Kuen OngHead of Department, Medicine & Endoscopy · b. 1967
  • Dr. Ramesh K. GurunathanHead of Department for General Surgery & Upper GIT · b. 1966
  • Dr. Mustafa Mohammed TaherHead of Outpatient Department · b. 1977
  • Ms. Lay Kim ChongCompany Secretary
  • Mr. Thiam Chai Tee MAICSACompany Secretary
  • Ms. Siew Yeen Wong MAISCACompany Secretary · b. 1970

Financials

Income Statement

Currency: MYR2020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Revenue39.18M63.47M64.44M70.28M66.82M80.00M73.21M
Growth (%)-+62.00%+1.53%+9.06%-4.92%+19.72%-8.49%
Cost of Revenue21.67M36.79M38.39M39.55M35.75M43.12M38.61M
Gross Profit17.51M26.68M26.05M30.73M31.07M36.87M34.59M
Gross Margin44.70%42.03%40.43%43.72%46.50%46.10%47.26%
Operating Expense10.40M11.99M13.09M16.24M17.86M17.84M20.48M
Operating Income7.12M14.69M12.97M14.49M13.21M19.03M14.12M
Operating Margin18.16%23.15%20.12%20.61%19.77%23.79%19.28%
EBITDA---21.28M21.34M24.89M19.82M
EBITDA Margin---30.28%31.94%31.12%27.08%
Net Income3.95M10.00M9.39M13.29M11.08M11.06M11.44M
Net Income Margin10.09%15.76%14.57%18.91%16.58%13.82%15.63%
Interest Expense1.58M1.22M846.36K734.32K601.99K386.00K189.00K
Interest Expense % of Total Revenue4.04%1.93%1.31%1.04%0.90%0.48%0.26%

Balance Sheet

Currency: MYR2019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Assets-47.09M45.98M119.54M131.73M132.44M180.49M224.00M
Total Liabilities-37.30M32.20M26.59M25.62M21.15M66.03M103.97M
Total Equity-9.79M13.78M92.95M106.11M111.30M114.46M120.02M
Cash-5.55M482.02K5.83M759.43K1.92M11.80M7.40M
Net Debt8.98M470.08K1.54M---31.02M76.10M

Cash Flow

Currency: MYR2020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Operating Cash Flow11.24M14.30M14.05M13.76M12.94M16.08M13.10M
Investing Cash Flow-603.07K-3.64M-47.93M50.65M---
Financing Cash Flow-6.24M-11.98M66.03M-2.50M---
Capital Expenditure610.08K1.70M427.67K2.13M15.73M37.26M81.35M
Free Cash Flow10.63M12.60M13.63M11.78M-2.80M-21.18M-68.25M
Dividends Paid7.28M7.28M6.06M6.06M6.16M8.08M5.83M
FCF to OCF94.57%88.12%96.96%85.62%-21.63%-131.74%-520.80%
Dividend Paid to FCF68.54%57.82%44.46%51.42%-220.26%-38.14%-8.54%

Earnings

Report DateJun 30, 2022Sep 30, 2022Dec 31, 2022May 30, 2023Aug 24, 2023Nov 24, 2023Feb 27, 2024May 28, 2024Aug 27, 2024Sep 30, 2024Jan 24, 2025May 29, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate-----------------
EPS Actual0.000.000.010.000.000.000.000.000.000.000.000.000.000.000.000.000.01
Surprise-----------------
Timing---Pre-marketPre-marketPre-marketAfter-hoursPre-marketPre-market-Pre-marketPre-market-----

Key Statistics & Ratios

Market Cap162.42M
Enterprise Value204.88M
Trailing P/E19.50
Forward P/E0.00
Price / Sales2.22
Price / Book1.39
EPS0.01
Book Value0.144
Revenue (TTM)73.21M
Gross Profit (TTM)34.59M
EBITDA18.36M
Profit Margin15.63%
Operating Margin19.70%
Return on Equity9.76%
Return on Assets4.18%
Shares Outstanding832.91M
Shares Float252.80M
Beta0.08
Dividend Yield0.32%
Dividend Rate0.00
Payout Ratio26.09%

Dividends

20262×
0.00Sep 11, 20260.00Feb 25, 2026
20252×
0.00Sep 18, 20250.01Feb 12, 2025
20242×
0.00Sep 10, 20240.00Mar 12, 2024
20232×
0.00Sep 7, 20230.00Mar 13, 2023
20221×
0.00Sep 9, 2022